Leo Cancer Care Receives FDA 510(k) Clearance for Marie® – A Revolutionary Upright Radiotherapy Platform
MIDDLETON, Wis., July 29, 2025 /PRNewswire/ -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Marie represents a paradigm shift in the delivery of particle therapy, combining an upright patient positioning system and...
ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025
Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continued product innovation via LifeSphere® NavaX™, strong new customer acquisition, and...
Fapon to Debut Shine mT8000 Open-Access, High Throughput Clinical Chemistry and Immunoassay Analyzer at ADLM 2025
CHICAGO, July 29, 2025 /PRNewswire/ -- Fapon, a global leading life sciences company, will debut its Shine mT8000 Fully Automated Clinical Chemistry and Immunoassay System at the ADLM 2025 Annual Scientific Meeting. This launch marks a significant milestone in Fapon's commitment to building an open, intelligent, and high-efficiency diagnostic ecosystem that helps clinical laboratories...
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance WuXi Biologics' leadership in end-to-end DP capabilities. SINGAPORE, July 29, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract...
Tigermed Completes Acquisition of Japanese CRO Micron
HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc. Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research...
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
SUZHOU, China, July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ). GC/GEJ is the fifth most common cancer and the fifth leading cause of cancer...
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions...
Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Company of the Year Recognition in the advanced visualization applications industry for its outstanding achievements in diagnostic innovation, seamless platform integration,...
XellSmart Completed World’s First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the world's first "off-the-shelf", allogeneic, iPSC-derived, spinal neural progenitor cell therapy targeting major neurological disorders, specifically spinal cord injury (SCI) – has commenced....
Big Lake Capital, LLC, Led and Controlled by NMHI CEO, Converts $671,984 Note into Nature’s Miracle (“NMHI”) Common Stocks
ONTARIO, Calif., July 28, 2025 /PRNewswire/ -- Nature's Miracle Holding Inc. (NMHI) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology announce that Big Lake Capital, LLC (the "Investor"), an investment company led and controlled by CEO Tie "James" Li, converted $678,290 into 3,425,706 NMHI shares at a conversion...
